Related Experiment Video

Updated: Jul 10, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

p53, BRCA1 and breast Cancer chemoresistance

Kimberly A Scata1, Wafik S El-Deiry

  • 1University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA.

Advances in Experimental Medicine and Biology
|November 13, 2007
PubMed

Insights

Tumor suppressor genes p53 and BRCA1 impact breast cancer treatment. p53 mutations cause resistance, while BRCA1 dysfunction increases sensitivity to chemotherapy and radiotherapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The tumor suppressor genes p53 and BRCA1 play critical roles in both hereditary and sporadic breast cancer.
  • These genes are implicated in cellular responses to DNA damage and therapeutic interventions.

Purpose of the Study:

  • To review clinical and preclinical data on the involvement of p53 and BRCA1 in breast cancer chemosensitivity.
  • To discuss the signaling pathways influenced by p53 and BRCA1 in modulating therapeutic responses.
  • To explore the implications of p53 and BRCA1 mutations in the design of cancer therapies.

Main Methods:

  • Review of existing clinical and preclinical data.
  • Analysis of signaling pathways downstream of p53 and BRCA1.
  • Discussion of mutation implications in therapeutic strategies.

Main Results:

  • p53 mutations are associated with resistance to chemotherapy and radiotherapy.
  • BRCA1 dysfunction correlates with enhanced sensitivity to DNA-damaging agents.
  • Cross-talk exists between p53 and BRCA1, including p53-mediated repression of BRCA1 transcription.

Conclusions:

  • p53 and BRCA1 status significantly influences breast cancer patient response to various therapies.
  • Understanding the interplay between p53 and BRCA1 is crucial for optimizing breast cancer treatment strategies.
  • Targeting or considering p53 and BRCA1 mutations can inform personalized therapeutic design.

More Related Videos

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...